Drug-induced rhabdomyolysis: From systems pharmacology analysis to biochemical flux

Chemical Research in Toxicology

Volumn 27, Issue 3, 2014, Pages 421-432

  Hur, Junguk ^a,b   Liu, Zhichao ^c   Tong, Weida ^c   Laaksonen, Reijo ^d   Bai, Jane P F ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ATORVASTATIN; CARNITINE PALMITOYLTRANSFERASE 2; CERIVASTATIN; ESTROGEN RECEPTOR ALPHA; FENOFIBRATE; GAMMA SYNUCLEIN; GEMFIBROZIL; JANUS KINASE 2; SIMVASTATIN; UBIQUITIN; UNCLASSIFIED DRUG; VALPROIC ACID;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG INTERACTION; DRUG SAFETY; ENERGY METABOLISM; FATTY ACID OXIDATION; FEEDBACK SYSTEM; FEMALE; GENE; GENE DRUG INTERACTION; GENE INTERACTION; HOMEOSTASIS; HUMAN; LIPID METABOLISM; MALE; MIDDLE AGED; OXIDATIVE PHOSPHORYLATION; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; RHABDOMYOLYSIS; TRANSCRIPTOMICS;

APOPTOSIS; CARNITINE O-PALMITOYLTRANSFERASE; DATABASES, FACTUAL; DOWN-REGULATION; ENERGY METABOLISM; ESTROGEN RECEPTOR ALPHA; GAMMA-SYNUCLEIN; GENE EXPRESSION PROFILING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JANUS KINASE 2; MUSCLE, SKELETAL; OXIDATIVE PHOSPHORYLATION; PHARMACEUTICAL PREPARATIONS; PROTEOLYSIS; RHABDOMYOLYSIS;

EID: 84896339730     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx400409c     Document Type: Article

References (40)

1. Issa, A. M., Phillips, K. A., Van Bebber, S., Nidamarthy, H. G., Lasser, K. E., Haas, J. S., Alldredge, B. K., Wachter, R. M., and Bates, D. W. (2007) Drug withdrawals in the United States: A systematic review of the evidence and analysis of trends Curr. Drug Saf. 2, 177-185
2. Vilar, S., Harpaz, R., Chase, H. S., Costanzi, S., Rabadan, R., and Friedman, C. (2011) Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: Application to rhabdomyolysis J. Am. Med. Inf. Assoc. 18, i73-80
3. van Vliet, A. K., Negre-Aminou, P., van Thiel, G. C., Bolhuis, P. A., and Cohen, L. H. (1996) Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscle Biochem. Pharmacol. 52, 1387-1392
4. Laaksonen, R., Katajamaa, M., Paiva, H., Sysi-Aho, M., Saarinen, L., Junni, P., Lutjohann, D., Smet, J., Van Coster, R., Seppanen-Laakso, T., Lehtimaki, T., Soini, J., and Oresic, M. (2006) A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle PloS One 1, e97-1-e97-9
5. Vladutiu, G. D., Simmons, Z., Isackson, P. J., Tarnopolsky, M., Peltier, W. L., Barboi, A. C., Sripathi, N., Wortmann, R. L., and Phillips, P. S. (2006) Genetic risk factors associated with lipid-lowering drug-induced myopathies Muscle Nerve 34, 153-162
6. Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J. P., Subramanian, A., Ross, K. N., Reich, M., Hieronymus, H., Wei, G., Armstrong, S. A., Haggarty, S. J., Clemons, P. A., Wei, R., Carr, S. A., Lander, E. S., and Golub, T. R. (2006) The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease Science 313, 1929-1935
7. Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., Gut, I., Lathrop, M., and Collins, R. (2008) SLCO1B1 variants and statin-induced myopathy- A genomewide study N. Engl. J. Med. 359, 789-799
8. Kottlors, M., Jaksch, M., Ketelsen, U. P., Weiner, S., Glocker, F. X., and Lucking, C. H. (2001) Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency Neuromuscular Disord. 11, 757-759
9. Wieser, T. (1993) Carnitine palmitoyltransferase II deficiency, In GeneReviews (Pagon, R. A., Bird, T. D., Dolan, C. R., Stephens, K., and Adam, M. P., Eds.) University of Washington, Seattle, WA.
10. Pasternak, R. C., Smith, S. C., Jr., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., and Lenfant, C. (2002) ACC/AHA/NHLBI clinical advisory on the use and safety of statins J. Am. Coll. Cardiol. 40, 567-572
11. ZOCOR (simvastatin) drug label, http://www.accessdata.fda.gov/drugsatfda- docs/label/2013/019766s090lbl.pdf.
12. Huang da, W., Sherman, B. T., and Lempicki, R. A. (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources Nat. Protoc. 4, 44-57
13. Huang da, W., Sherman, B. T., and Lempicki, R. A. (2009) Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists Nucleic Acids Res. 37, 1-13
14. Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing J. R. Stat. Soc., Series B 57, 289-300
15. Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., and di Bernardo, D. (2010) Discovery of drug mode of action and drug repositioning from transcriptional responses Proc. Natl. Acad. Sci. U.S.A. 107, 14621-14626
16. Barrey, E., Jayr, L., Mucher, E., Gospodnetic, S., Joly, F., Benech, P., Alibert, O., Gidrol, X., Mata, X., Vaiman, A., and Guerin, G. (2012) Transcriptome analysis of muscle in horses suffering from recurrent exertional rhabdomyolysis revealed energetic pathway alterations and disruption in the cytosolic calcium regulation Anim. Genet. 43, 271-281
17. Crane, F. L. (2001) Biochemical functions of coenzyme Q10 J. Am. Coll. Nutr. 20, 591-598
18. Tanaka, S., Sakamoto, K., Yamamoto, M., Mizuno, A., Ono, T., Waguri, S., and Kimura, J. (2010) Mechanism of statin-induced contractile dysfunction in rat cultured skeletal myofibers J. Pharmacol. Sci. 114, 454-463
19. Truica, C. I. and Frankel, S. R. (2002) Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: Case report and review of literature Am. J. Hematol. 70, 320-323
20. Kang, J. and Rivest, S. (2012) Lipid metabolism and neuroinflammation in Alzheimer's disease: A role for liver X receptors Endocr. Rev. 33, 715-746
21. Vanholder, R., Sever, M. S., Erek, E., and Lameire, N. (2000) Rhabdomyolysis J. Am. Soc. Nephrol. 11, 1553-1561
22. Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., and Niemi, M. (2006) SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid Pharmacogenet. Genomics 16, 873-879
23. Knauer, M. J., Urquhart, B. L., Meyer zu Schwabedissen, H. E., Schwarz, U. I., Lemke, C. J., Leake, B. F., Kim, R. B., and Tirona, R. G. (2010) Human skeletal muscle drug transporters determine local exposure and toxicity of statins Circ. Res. 106, 297-306
24. Gordon, L. I., Burke, M. A., Singh, A. T., Prachand, S., Lieberman, E. D., Sun, L., Naik, T. J., Prasad, S. V., and Ardehali, H. (2009) Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways J. Biol. Chem. 284, 2080-2087
25. Zeng, F., Xu, J., and Harris, R. C. (2009) Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK II cells FASEB J. 23, 1935-1945
26. Ren, Z. and Schaefer, T. S. (2002) ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner J. Biol. Chem. 277, 38486-38493
27. Zhong, Z., Wen, Z., and Darnell, J. E., Jr. (1994) Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6 Science 264, 95-98
28. Morikawa, S., Murakami, T., Yamazaki, H., Izumi, A., Saito, Y., Hamakubo, T., and Kodama, T. (2005) Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins J. Atheroscler. Thromb. 12, 121-131
29. Wagner, B. K., Kitami, T., Gilbert, T. J., Peck, D., Ramanathan, A., Schreiber, S. L., Golub, T. R., and Mootha, V. K. (2008) Large-scale chemical dissection of mitochondrial function Nat. Biotechnol. 26, 343-351
30. Jula, A., Marniemi, J., Huupponen, R., Virtanen, A., Rastas, M., and Ronnemaa, T. (2002) Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial JAMA, J. Am. Med. Assoc. 287, 598-605
31. Larsen, S., Stride, N., Hey-Mogensen, M., Hansen, C. N., Bang, L. E., Bundgaard, H., Nielsen, L. B., Helge, J. W., and Dela, F. (2013) Simvastatin effects on skeletal muscle: Relation to decreased mitochondrial function and glucose intolerance J. Am. Coll. Cardiol. 61, 44-53
32. Ruano, G., Windemuth, A., Wu, A. H., Kane, J. P., Malloy, M. J., Pullinger, C. R., Kocherla, M., Bogaard, K., Gordon, B. R., Holford, T. R., Gupta, A., Seip, R. L., and Thompson, P. D. (2011) Mechanisms of statin-induced myalgia assessed by physiogenomic associations Atherosclerosis 218, 451-456
33. Ruano, G., Thompson, P. D., Windemuth, A., Seip, R. L., Dande, A., Sorokin, A., Kocherla, M., Smith, A., Holford, T. R., and Wu, A. H. (2007) Physiogenomic association of statin-related myalgia to serotonin receptors Muscle Nerve 36, 329-335
34. Isackson, P. J., Ochs-Balcom, H. M., Ma, C., Harley, J. B., Peltier, W., Tarnopolsky, M., Sripathi, N., Wortmann, R. L., Simmons, Z., Wilson, J. D., Smith, S. A., Barboi, A., Fine, E., Baer, A., Baker, S., Kaufman, K., Cobb, B., Kilpatrick, J. R., and Vladutiu, G. D. (2011) Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: evidence for additional functions of EYS Muscle Nerve 44, 531-538
35. Vladutiu, G. D., Isackson, P. J., Kaufman, K., Harley, J. B., Cobb, B., Christopher-Stine, L., and Wortmann, R. L. (2011) Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies Mol. Genet. Metab. 104, 167-173
36. Marciante, K. D., Durda, J. P., Heckbert, S. R., Lumley, T., Rice, K., McKnight, B., Totah, R. A., Tamraz, B., Kroetz, D. L., Fukushima, H., Kaspera, R., Bis, J. C., Glazer, N. L., Li, G., Austin, T. R., Taylor, K. D., Rotter, J. I., Jaquish, C. E., Kwok, P. Y., Tracy, R. P., and Psaty, B. M. (2011) Cerivastatin, genetic variants, and the risk of rhabdomyolysis Pharmacogenet. Genomics 21, 280-288
37. Anichini, A., Fanin, M., Vianey-Saban, C., Cassandrini, D., Fiorillo, C., Bruno, C., and Angelini, C. (2011) Genotype-phenotype correlations in a large series of patients with muscle type CPT II deficiency Neurol. Res. 33, 24-32
38. Isackson, P. J., Bennett, M. J., and Vladutiu, G. D. (2006) Identification of 16 new disease-causing mutations in the CPT2 gene resulting in carnitine palmitoyltransferase II deficiency Mol. Genet. Metab. 89, 323-331
39. Thuillier, L., Rostane, H., Droin, V., Demaugre, F., Brivet, M., Kadhom, N., Prip-Buus, C., Gobin, S., Saudubray, J. M., and Bonnefont, J. P. (2003) Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 (CPT2) deficiency Hum. Mutat. 21, 493-501
40. Vockley, J., Rinaldo, P., Bennett, M. J., Matern, D., and Vladutiu, G. D. (2000) Synergistic heterozygosity: Disease resulting from multiple partial defects in one or more metabolic pathways Mol. Genet. Metab. 71, 10-18